Rectal Examination for Prostate Cancer

A digital rectal examination (DRE) is one of the simplest methods for assessing the state of the prostate gland. This may be performed as part of a routine check of the prostate gland or in the case of symptoms such as severe constipation, bleeding or pain from the anus or bowel incontinence.

The DRE process

Although the procedure is not usually painful, it can be uncomfortable and a local anesthetic may be applied in the form of a gel or a cream to numb the area. In the case of particularly apprehensive individuals, a sedative may be administered.

The test is performed by a nurse or doctor. The patient is asked to remove their lower garments and lie on their left side with their knees drawn up to the chest. Women who undergo the procedure may be asked to lie on their backs with their legs raised.

The examination begins with a careful check of the area and skin around the anus to check for symptoms such as rashes, bleeding, warts, tearing or fissures and swollen blood vessels. The nurse or doctor then inserts a gloved and lubricated finger, usually the index finger, into the rectum and the patient is asked to squeeze their anus to test the strength of their anal sphincter muscles. The finger is then pressed against the front wall of the rectum to feel the prostate gland.

If the prostate is healthy, it feels smooth, while an enlarged prostate may be felt as a bulge. If the prostate is enlarged, it will still feel smooth in the case of benign prostatic hyperplasia (BPH) but if cancer is present, the gland may feel hard and lumpy. The prostate may be painful when squeezed if it is inflamed or infected. The whole test may take around five minutes.

DRE only forms part of the testing performed in the diagnosis of prostate cancer. The examination is not specific for prostate cancer and is used in combination with a blood test to check for prostate-specific antigen (PSA) level, a biomarker for prostate cancer, as well as a biopsy to check prostate tissue for the presence of cancer cells. DRE is also performed as a way of monitoring individuals who have already been diagnosed with prostate cancer, to check for changes that may indicate recurrence of the cancer after treatment.

Rectal examination of the prostate

Further Reading

Last Updated: Jan 2, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, January 02). Rectal Examination for Prostate Cancer. News-Medical. Retrieved on July 19, 2024 from

  • MLA

    Mandal, Ananya. "Rectal Examination for Prostate Cancer". News-Medical. 19 July 2024. <>.

  • Chicago

    Mandal, Ananya. "Rectal Examination for Prostate Cancer". News-Medical. (accessed July 19, 2024).

  • Harvard

    Mandal, Ananya. 2023. Rectal Examination for Prostate Cancer. News-Medical, viewed 19 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?